Investor resources
Why Invest?
Investment Highlights
Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study successfully completed demonstrating strong safety and a 67% Complete Response (“CR”) rate for patients treated at the therapeutic dose.
In-progress pivotal Phase II NMIBC clinical study under since November 2020.
Patented light-activated Photo Dynamic Compounds ("PDCs") have been scientifically and preclinically researched for 18+ years to optimize their ability to destroy cancer, bacteria and viruses.
Over 10+ peer reviewed published research publications.
Primary: NMIBC
Secondary: Non-Small Cell Lung Cancer ("NSCLC") , GlioBlastoma Multiforme ("GBM"), Vaccine for various enveloped viruses.
Contact Information
Transfer Agent:
TMX Equity Transfer Services Inc.
100 Adelaide Streety West, Suite 301,
Toronto, Ontario
M5H 1S3, CANADA
Work: 416-361-0930
Website: www.tsxtrust.com
Auditor:
Richter LLP
181 Bay Street, Suite 3510
Bay Wellington Tower
Toronto, Ontario
M5J 2T3, CANADA
Work: 416-488-2345
Fax: 416-488-3765
Web: www.richter.ca
Chief Financial Officer/Investor Relations
Kristina Hachey, CPA
Theralase Technologies Inc.
41 Hollinger Road,
Toronto, Ontario
M4B 3G4, CANADA
Work: 416-699-5373 ext. 224
Email: khachey@theralase.com
Website: theralase.com
Investor Information
Data last updated on June 27, 2022
- TSX Venture Exchange (TSXV: TLT)
- Over-The-Counter Exchange (OTCQB: TLTFF)
Share Price: C$0.345
Market Capital: $CAN 70.9 M
Warrants: 67,768,615
Shares Outstanding: 204,425,875
Stock Options: 10,440,000
For Investor Relations please contact: Investor Information Theralase®
Our Partners
As part of our continuing mission to design, develop, and manufacture cutting-edge laser technologies, Theralase® has partnered with individuals and groups at the following institutions and organizations.
